| Bioactivity | Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) . |
| Name | Dehydrovomifoliol |
| CAS | 39763-33-2 |
| Formula | C13H18O3 |
| Molar Mass | 222.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. MaJ, et al. Dehydrovomifoliol Alleviates Nonalcoholic FattyLiver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and MolecularDocking Study. Evid Based Complement Alternat Med. 2023 Feb 1;2023:9107598. |
Dehydrovomifoliol
CAS: 39763-33-2 F: C13H18O3 W: 222.28
Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.